[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"impacted-third-molar-tooth\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:impacted-third-molar-tooth":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,69,91,111,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100600211","phase-2-jaw-muscle-pain-post-wisdom-molar-surgery-100600211",false,"NCT07094542","Jaw Muscle Pain Post Wisdom Molar Surgery","Temporo-masseteric Nerve Block in Post-wisdom Tooth Extraction Pain- a Randomized Study","Inclusion Criteria:\n\nAll patients recommended extraction\u002Fs of at least 1 lower wisdom (third) molar that is partially\u002Ffully 'impacted' under intravenous sedation, are eligible to participate in this study so long as they\n\n* are 18 years or older,\n* are healthy,\n* have no cognitive\u002Fintellectual disability,\n* have no past\u002Frecent pain or reduced range of motion in their jaw joint\u002F muscle complex, no trauma or surgery in their jaw region.\n* have an electronic device such as a smart phone or a tablet\u002F computer with internet connection.\n* are willing to participate in the study and not be excluded by the following criteria below.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Compromised ability to guard their self-interest, for e.g., prisoners, children, pregnant women, patients with intellectual\u002Fcognitive disability are not enrolled in the study.\n* Those patients who present with infection\u002Finflammation involving the third molars slated for extractions, on the day of their procedure, may not take part in the study.\n* Those who have had opioid pain medication\u002Fs in the past 3 months to address short term or long-standing pain, or those who are on long term prescription of anti-inflammatory pain medication, are unable to participate.\n* Those with long standing painful limitation of movement of the jaw joint or muscles.\n* Those patients who are allergic to\u002Funable to tolerate either the dental local anesthetic or its components, opioids, acetaminophen or ibuprofen also may not take part in the study","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The proposed design is a triple-blind, placebo-controlled randomized prospective phase II trial to assess the feasibility of employing the Temporo-masseteric Nerve Block (TMNB) injection to decrease jaw muscle pain, overall pain, improve mouth opening and minimize pain medication consumption. 80 participants undergoing lower third molar removal under sedation will be enrolled. Those who develop significant jaw muscle pain on the following day will be randomized to receive either the TMNB injection or a placebo. Daily ecological momentary assessments (EMAs) will be collected reflecting elements of patient experience for all participants. On Day 8, participants return for an end-of-study evaluation and return their unused pain medications. Up to 40 participants who are randomized to receive TMNB\u002Fplacebo will be recruited to participate in a qualitative interview regarding their experience.",[26,27,28],"Post Operative Pain","Impacted Third Molar Tooth","Muscle Pain",[30,31],"Temporo-masseteric Nerve Block","Jaw muscle pain","NOT_YET_RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":20},"2026-09",{"date":40,"type":20},"2030-05",{"name":42,"class":43},"Rutgers, The State University of New Jersey","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100557563","variability-in-analgesic-response-to-ibuprofen-100557563","NCT06539741","Variability in Analgesic Response to Ibuprofen","Mechanisms of Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Ability to take oral medication and be willing to adhere to the study treatment regimen\n4. Men and women greater than 18 years of age requiring extraction of at least one impacted mandibular third molar tooth (at least 50% covered with bone).\n5. Absence of other major medical problems or contraindications to surgery or study drugs.\n6. Female subjects of child bearing potential must be using a medically acceptable method of contraception (oral contraception, Depo-Provera injection, IUD, condom with spermicide, diaphragm, cervical cap, progestin implant, abstinence, tubal ligation, oophorectomy, TAH) throughout the entire study period. All female subjects must consent to a urine pregnancy test at screening and a urine pregnancy test on the day of surgery, which must be negative at all time points.\n7. Has not ingested caffeine-containing products within 12 hours of surgery.\n8. All subjects must consent to a urine drug test at screening. Results must be negative (except for THC) unless the subject is on a stable dose of a non-analgesic drug for a legitimate medical purpose. A positive test for THC will be permitted and the frequency of use will be documented. A positive result will be reported to the subject.\n9. Does not consume more than 1 alcoholic beverage per day on average.\n10. Subjects must reach a level of at least moderate pain within four hours of surgery completion, with a pain score greater than or equal to 4 on a 0-10 numerical pain scale\n11. Subjects must be willing and able to complete safety and efficacy diaries.\n12. An escort must be available to pick up the subject at the end of at the end of the surgical\u002Fdosing visit (Visit #2).\n\nExclusion Criteria:\n\n1. Female subjects who are pregnant or nursing a child.\n2. Subjects who have received an investigational drug or used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening.\n3. Subjects who are sensitive or allergic to ibuprofen, acetaminophen, or their components.\n4. Subjects who are sensitive or allergic to aspirin or other NSAIDs.\n5. Subjects who are sensitive or allergic to oxycodone or other opioids (excluding nausea and constipation).\n6. Presence of a serious medical condition (e.g. poorly controlled hypertension or diabetes, gastrointestinal disorders such as bleeding ulcer, coagulation or bleeding disorders, significantly impaired cardiac, renal, hepatic, respiratory, or thyroid function) that according to the investigator may interfere with interpretation of the study results or compromise the safety of a potential subject.\n7. Acute local infection at the time of surgery that could confound post-surgical evaluation.\n8. Use of any confounding prescription or non-prescription drug within 24 hours of the surgical procedure, including analgesics, sedating antihistamine, sedative, alcohol, or CNS\u002Fpsychotropic agents (i.e. sleep aids, benzodiazepines). Hormonal contraceptives, hormone replacement therapy (including males taking testosterone as a hormone replacement to treat a documented low testosterone level), or thyroid replacement hormones are allowed. Individuals taking other\u002Fadditional chronic stable medications can be considered on a case-by-case basis for inclusion in the study if agreed upon by judgment of the investigator.\n9. Subjects with any abnormal laboratory value or physical finding that according to the investigator may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject.\n10. Subjects who have a history of opioid use disorder or other substance use disorder, based upon history and judgment of the Investigator.\n11. Subjects who are unwilling to provide a blood sample for genetic analyses.\n12. Employees of the principal investigator, sub-investigators, or relative of an employee who is directly involved in this study.",true,{"count":54,"type":20},200,"OBSERVATIONAL","Nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, are recommended as first-line treatment for post-surgical dental pain. However, there is variability in analgesic response, and some patients require supplemental opioids for adequate pain relief. The goal of this study is to identify the factors that contribute to the need for opioid after third molar extraction to help limit unnecessary opioid prescriptions in patients who will have good pain relief with ibuprofen alone.",[27,58],"Pain, Acute","RECRUITING","2026-05-04",{"date":62,"type":36},"2026-05-06",{"date":64,"type":36},"2025-01-03",{"date":66,"type":20},"2027-09",{"name":68,"class":43},"University of Pennsylvania",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100618369","phase-3-lidocaine-patch-and-lower-third-molar-100618369","NCT07330726","Lidocaine Patch and Lower Third Molar","The Efficacy of a Transmucosal Lidocaine Patch on Postoperative Pain Following Mandibular Third Molar Extraction","Inclusion Criteria:\n\n* • Age ≥18ys\n\n  * no systemic disease\n  * impacted mandibular third molar class II position B on Pell- Gregory classification\n\nExclusion Criteria:\n\n* • history of metabolic or systemic diseases affecting bone or healing process,\n\n  * local infection,\n  * tobacco use,\n  * oral contraceptive,\n  * pregnancy and lactation\n  * patients who had taken analgesics or anti-inflammatories for 1 week prior to enrollment in the study.",{"count":77,"type":20},21,[79],"PHASE3","* Completed medical and dental history will take for all patients and the position of the impacted teeth will evaluate by panoramic films. Patients will fully inform about the treatment procedures, follow-up examinations and complications of surgical procedures.\n* Full thickness mucoperiosteal flap will be raised to expose sufficient bone on lateral and distal aspect of the impacted molar. Removal of bone will be done with stainless steel bur under Constant irrigation with normal saline while removing bone to prevent thermal necrosis.\n* When necessary, sectioning of crown and roots will be performed with a fissure bur. After tooth extraction, the alveolus will be inspected, curetted, and irrigated with 0.9% sterile saline solution.\n* Surgical removal of impacted mandibular third molar will be done,1% metformin gel or placebo gel in the socket following removal of the impacted third molar .\n* The mucoperiosteal flap will be repositioned and sutured with 3-0 black silk suture.\n* Control side : use transmucosal placebo patch\n* Study side: use transmucosal lidocaine patch Postoperative care\n* Postoperatively, the patients were instructed to apply ice bags 20 min\u002Fhour for the next 6 hours to the surgical side, eat soft cold diet by the aid of a straw and to avoid hot diet and fluid on the day of surgery.\n* Sutures were removed after 7 days postoperatively.\n* All the patients will be evaluated on the 1st, 3rd, and 7th postoperative days for pain, preoperative and postoperative mouth opening, and degree of postoperative swelling.",[27],"2025-12-28",{"date":84,"type":36},"2026-01-09",{"date":86,"type":20},"2026-01-01",{"date":88,"type":20},"2026-04-30",{"name":90,"class":43},"Fayoum University",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100591085","phase-2-local-metformin-gel-and-impacted-lower-third-molar-100591085","NCT06975839","Local Metformin Gel and Impacted Lower Third Molar","Evaluate the Efficacy of Local Metformin Gel Application Following Surgical Removal of Mandibular Third Molar","Inclusion Criteria:\n\n* • Age ≥18ys\n\n  * no systemic disease\n  * impacted mandibular third molar class II position B on Pell- Gregory classification\n\nExclusion Criteria:\n\n* • history of metabolic or systemic diseases affecting bone or healing process,\n\n  * local infection,\n  * tobacco use,\n  * oral contraceptive,\n  * pregnancy and lactation\n  * patients who had taken analgesics or anti-inflammatories for 1 week prior to enrollment in the study",{"count":99,"type":20},36,[23],"* Completed medical and dental history will take for all patients and the position of the impacted teeth will evaluate by panoramic films. Patients will fully inform about the treatment procedures, follow-up examinations and complications of surgical procedures.\n* The study will be carried out as a randomized controlled clinical trial. Randomly, by the use of predefined computer-generated randomization table, the eligible patients will be randomized in equal proportions between Study group: patients will receive 1% Metformin gel in the socket following removal of the impacted third molar and Control group: patients will receive placebo gel 2% hydroxymethyl cellulose.All surgeries will be performed under complete aseptic conditions. Before surgery, the patient's mouth will be rinsed with a chlorhexidine digluconate solution 0.2% for 2 minutes. Surgery will carry out under local anesthesia consisting of 4% articain hydrochloride with 1:100,000 adrenaline.\n* Full thickness mucoperiosteal flap will be raised to expose sufficient bone on lateral and distal aspect of the impacted molar. Removal of bone will be done with stainless steel bur under Constant irrigation with normal saline while removing bone to prevent thermal necrosis.\n* When necessary, sectioning of crown and roots will be performed with a fissure bur. After tooth extraction, the alveolus will be inspected, curetted, and irrigated with 0.9% sterile saline solution.\n* Surgical removal of impacted mandibular third molar will be done,1% metformin gel or placebo gel in the socket following removal of the impacted third molar .\n* The mucoperiosteal flap will be repositioned and sutured with 3-0 black silk suture.",[27],"2025-05-09",{"date":105,"type":36},"2025-05-16",{"date":107,"type":20},"2025-06-01",{"date":109,"type":20},"2026-02-01",{"name":90,"class":43},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":52,"sex":16,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":44},"100540732","assessment-of-vertical-pattern-in-correlation-with-third-molar-inclusion--a-3d-cbct-analysis-100540732","NCT06320665","Assessment of Vertical Pattern in Correlation With Third Molar Inclusion : A 3D CBCT Analysis","Assessment of Vertical Pattern in Correlation With Third Molar Inclusion : a 3D CBCT Analysis","Inclusion Criteria:\n\n* CMV stage 5 on lateral radiography (end of growth)\n* at least one impacted third molar at minimum Nolla stage 6 development\n\nExclusion Criteria:\n\n* Previous maxillofacial trauma\n* Growing patients\n* Missing permanent tooth or early avulsion\n* Dysplasia\n* Dentofacial deformities\n* Endocrinological pathologies with implications for maxillofacial growth\n* Syndromes\n* History of maxillofacial or orthognathic surgery\n* History of orthodontic treatment\n* Incomplete data","15 Years",{"count":19,"type":20},"The objective is to compare the sagittal and vertical skeletal parameters of patients with an impacted third molar.\n\nPatients will be analyzed according to their skeletal characteristics: skeletal class (sagittal direction) and facial skeletal typology (vertical direction).\n\nThe inclusion characteristics of third molars will also be analyzed, to see the links between typology and inclusion. The principal hypothesis is no significant difference in third molar inclusion patterns in relation to skeletal divergence.",[27],[123,124,125,126,127,128,129],"Cone beam ct","third molar","Vertical dimension","Impacted teeth","Orthodontic","Adult","Skeletal pattern","2025-03-25",{"date":132,"type":36},"2025-03-28",{"date":134,"type":36},"2024-12-01",{"date":136,"type":20},"2025-09-30",{"name":138,"class":43},"Central Hospital, Nancy, France",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":44},"100542139","fracture-pattern-following-bilateral-sagittal-split-osteotomy-with-or-without-impacted-third-molars-100542139","NCT06338982","Fracture Pattern Following Bilateral Sagittal Split Osteotomy With or Without Impacted Third Molars","Fracture Pattern Following Bilateral Sagittal Split Osteotomy With or Without Impacted Third A Randomized Controlled Trial Assessing Fracture Pattern, Condylar Segment Positioning, Complications and Patient-reported Outcome Measures","Inclusion Criteria:\n\n* Patients scheduled for surgical correction of facial deformities involving BSSO or bimaxillary surgery with bilateral asymptomatic impacted mandibular third molars\n* Age between 18 and 75 years\n\nExclusion Criteria:\n\n* Fully erupted and well-functioning mandibular third molar\n* Unilateral impacted mandibular third molar\n* Pathology associated with the impacted mandibular third molar\n* BSSO combined with genioplasty\n* Previous mandibular fractures\n* Present neurosensory disturbances of the inferior alveolar nerve\n* Systemic bone disease or arthritis\n* Physical status classification system, ASA Class III or IV, specified patients with severe systemic disease ore patients with severe systemic disease that is constant threat to life\n* Failure to attend the entire observation period","75 Years",{"count":148,"type":20},150,[150],"NA","The goal of this clinical trial is to investigate the hypothesis that there are none difference in the treatment result of orthognathic surgery on the lower jaw, with interoperative wisdom tooth removal rather than preoperative wisdom tooth removal. In patients with severe dental malocclusion combined with a dentofacial deformity. The main question it aims to answer are:\n\n• Is there a difference in the degree of complication and the patient's perception, with inter-operative wisdom tooth removal rather than pre-operative wisdom tooth removal.\n\nParticipants will be will be divided into two groups, with one group having their wisdom teeth removed 6 months before their jaw moving surgery and the other group having their wisdom teeth removed in connection with their jaw moving surgery.",[27,153,154,155],"Osteotomy","Orthognathic Surgery","Mandibular Fractures","2024-03-24",{"date":158,"type":36},"2024-04-01",{"date":160,"type":20},"2024-03-30",{"date":162,"type":20},"2030-10-31",{"name":164,"class":43},"Kimie Bols Østergaard"]